Parallax Volatility Advisers’s Aimmune Therapeutics AIMT Stock Holding History

Parallax Volatility Advisers’s Portfolio AIMT Stock Details AIMT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q1	–	Sell	-85,000	Closed	-$2.85M	–	2885
2019 Q4	$2.85M	Buy	+85,000	New	+$2.38M	﹤0.01%	1130
2019 Q3	–	Sell	-49,000	Closed	-$1.02M	–	3841
2019 Q2	$1.02M	Hold	49,000	–	–	﹤0.01%	1268
2019 Q1	$1.09M	Buy	49,000 +9,000	+23%	+$212K	﹤0.01%	1245
2018 Q4	$956K	Sell	40,000 -20,000	-33%	-$518K	﹤0.01%	1326
2018 Q3	$1.64M	Buy	60,000 +40,000	+200%	+$1.13M	﹤0.01%	1092
2018 Q2	$538K	Buy	+20,000	New	+$612K	﹤0.01%	1253

Parallax Volatility Advisers's AIMT Position: Q4 2020 in Review

Parallax Volatility Advisers sold out of Aimmune Therapeutics (AIMT) in Q4 2020, closing a stake of 8,442 shares — an estimated $291K sold.

Parallax Volatility Advisers first reported a position in AIMT in Q4 2017 and held it in 6 quarters. The position peaked at $755K in Q4 2019. 0 funds tracked by Wall St. Rank hold AIMT as of Q4 2020.

Parallax Volatility Advisers reported no remaining Aimmune Therapeutics position as of Q4 2020 after selling out during the quarter.
Parallax Volatility Advisers sold 8,442 Aimmune Therapeutics shares in Q4 2020, an estimated $291K.
Parallax Volatility Advisers first reported a position in Aimmune Therapeutics in Q4 2017 and held it in 6 quarters.
Parallax Volatility Advisers's Aimmune Therapeutics position peaked at $755K in Q4 2019.
0 funds tracked by Wall St. Rank held Aimmune Therapeutics as of Q4 2020.

Based on Parallax Volatility Advisers's 13F filing for Q4 2020, filed 16 Feb 2021.